|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:bioavailability
|
gptkb:Mvasi
Zirabev
Amsparity
|
|
gptkbp:brand
|
gptkb:Avastin
|
|
gptkbp:can_be_combined_with
|
radiation therapy
chemotherapy
|
|
gptkbp:chemical_formula
|
C663 H1028 N180 O217 S4
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:contraindication
|
active bleeding
severe hypertension
recent surgery
|
|
gptkbp:counseling_services
|
inform about potential side effects
avoid pregnancy during treatment
report signs of infection
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
lyophilized powder
|
|
gptkbp:drug_interactions
|
anticoagulants
antiplatelet agents
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bevacizumab
|
|
gptkbp:indication
|
gptkb:disease
gptkb:Oncology
|
|
gptkbp:invention
|
gptkb:2019
|
|
gptkbp:is_monitored_by
|
blood pressure
renal function
signs of bleeding
|
|
gptkbp:lifespan
|
20 days
|
|
gptkbp:marketed_as
|
gptkb:Avastin
|
|
gptkbp:mechanism_of_action
|
inhibits angiogenesis
|
|
gptkbp:research
|
gptkb:Ophthalmology
diabetic retinopathy
ocular diseases
other malignancies
wet macular degeneration
|
|
gptkbp:rounds
|
hepatic
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:side_effect
|
hypertension
bleeding
proteinuria
thromboembolism
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:vascular_endothelial_growth_factor_(VEGF)
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:weight
|
149 k Da
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
gptkb:Avastin
|
|
gptkbp:bfsLayer
|
5
|